Search Results

You are looking at 1 - 10 of 41 items for :

  • "pamidronate" x
  • User-accessible content x
Clear All
Full access

Richard L. Theriault

. 9 Hortobagyi GN Theriault RL Lipton A . Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group . J Clin Oncol 1998 ; 16 : 2038 – 2044 . 10 Libshitz

Full access

Davide Mauri, Antonis Valachis, Nikolaos P. Polyzos, Lamprini Tsali, Dimitris Mavroudis, Vassilis Georgoulias, and Giovanni Casazza

algorithm was used: [early OR adjuvant] AND [breast OR mammary] AND [tumour OR malign * OR carcinom * OR cancer] AND [biphosphonates OR bisphosphonates OR clodronate OR pamidronate OR zoledronic acid OR ibandronate]. The reference lists of all studies

Full access

Paul S. White, Michael Dennis, Eric A. Jones, Janice M. Weinberg, and Shayna Sarosiek

Background Bone-modifying agents (BMAs) are an important component of supportive care for many patients with cancer. These agents include the intravenously administered bisphosphonates pamidronate and zoledronic acid, in addition to denosumab, a

Full access

Siyang Leng, Yizhen Chen, Wei-Yann Tsai, Divaya Bhutani, Grace C. Hillyer, Emerson Lim, Melissa K. Accordino, Jason D. Wright, Dawn L. Hershman, Suzanne Lentzsch, and Alfred I. Neugut

morbidity of bone disease in these patients, guidelines from NCCN, ASCO, International Myeloma Working Group, and European Myeloma Network all recommend use of the bisphosphonates zoledronic acid and pamidronate in patients receiving primary MM therapy. 2

Full access

Harold J. Burstein

guideline recommended using 1 of 3 treatments: denosumab, zoledronic acid, or pamidronate. The NCCN Guidelines for Breast Cancer 2 also recommend the exact same 3 drugs (to view the most recent version of these guidelines, visit the NCCN Web site at NCCN

Full access

Noopur S. Raje, Andrew J. Yee, and G. David Roodman

Bisphosphonates Bisphosphonates, such as pamidronate and zoledronate, play a fundamental role in minimizing and managing bone-related complications in MM. 14 , 15 Bisphosphonates are drugs that share a phosphorus-carbon-phosphorus backbone and accumulate in the

Full access

Marc Fishman, William Shimp, James Krook, Akhil Kumar, and William J.M. Hrushesky

medications and should be changed. Using Dr. Burstein's example, at Medicare allowable rates, pamidronate costs $29 per month and the physician's office loses $7 on drug costs; zoledronic acid costs $904 per month and the physician's office makes approximately

Full access

Mohamad A. Hussein

2002 ; 70 : 11 – 19 . 25. Berenson JR Lichtenstein A Porter L . Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma . Myeloma Aredia Study Group . N Engl J Med 1996 ; 334 : 488 – 493 . 26

Full access

Julie R. Gralow, J. Sybil Biermann, Azeez Farooki, Monica N. Fornier, Robert F. Gagel, Rashmi N. Kumar, Charles L. Shapiro, Andrew Shields, Matthew R. Smith, Sandy Srinivas, and Catherine H. Van Poznak

2003 ; 169 : 2008 – 2012 . 47 Smith MR McGovern FJ Zeitman AL . Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer . N Engl J Med 2001 ; 345 : 948 – 955 . 48 Tauchmanova L Colao A Lombardi

Full access

Harold J. Burstein

;10:425–426) that noted that 3 bone-modifying agents (denosumab, zoledronic acid, and pamidronate) were all endorsed by NCCN and ASCO guidelines. Yet these agents differ markedly in logistics and cost. Are they really all equally preferred? On what grounds? At